Skip to main content

Dermatologic Side Effects of Systemic Anticancer Therapy

  • Chapter
  • First Online:

Abstract

Skin, hair, and nails are almost always modified by systemic cancer therapies. These changes can sometimes result in severe adverse events, but most of the patients present with light and moderate skin side effects. Nevertheless, these ­dermatologic manifestations can significantly impact patients’ quality of life, especially in the case of new targeted agents that are sometimes prescribed continuously over long periods of time.

Patients have to be informed in advance about the skin symptoms that might occur during the course of their treatments. Preventive and symptomatic measures can be advised or prescribed that might optimize treatment compliance and improve quality of life.

Close interaction between oncologists and dermatologist is warranted in order to describe, characterize, and manage the numerous and sometimes new and original skin manifestations of new cancer therapies. In this chapter, we will focus on the side effects associated with new targeted anticancer agents since oncologists and physicians are less informed about this field than they are about skin side effects of classical chemotherapeutic agents.

Keywords

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Robert C, Soria J-C, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491–500.

    Article  PubMed  CAS  Google Scholar 

  2. Agero ALC, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006;55(4):657–70.

    Article  PubMed  Google Scholar 

  3. Osio A, Mateus C, Soria J-C, Massard C, Malka D, Boige V, et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol. 2009;161(3):515–21.

    Article  PubMed  CAS  Google Scholar 

  4. Laux I, Jain A, Singh S, Agus DB. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer. 2006;94(1):85–92.

    Article  PubMed  CAS  Google Scholar 

  5. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803–12.

    Article  PubMed  CAS  Google Scholar 

  6. Surguladze D, Deevi D, Claros N, Corcoran E, Wang S, Plym MJ, et al. Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res. 2009;69(14):5643–7.

    Article  PubMed  CAS  Google Scholar 

  7. Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park, NY). 2003;17(11 Suppl 12):23–8.

    Google Scholar 

  8. Amador ML, Oppenheimer D, Perea S, Maitra A, Cusatis G, Cusati G, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 2004;64(24):9139–43.

    Article  PubMed  CAS  Google Scholar 

  9. Lacouture ME. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. Cancer Nurs. 2007;30(4 Suppl 1):S17–26.

    Article  PubMed  Google Scholar 

  10. Janus N, Launay-Vacher V, Robert C, Souquet P-J, Mateus C, Dreno B, et al. Description of erlotinib-related skin effects management in France. Results of the PRECEDE study. Cancer Radiother. 2009;13(2):97–102.

    Article  PubMed  CAS  Google Scholar 

  11. Akman A, Yilmaz E, Mutlu H, Ozdogan M. Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol. 2009;34(5):e202–4.

    Article  PubMed  CAS  Google Scholar 

  12. Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, Pujol J-L, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol. 2004;151(1):238–41.

    Article  PubMed  CAS  Google Scholar 

  13. Scope A, Agero ALC, Dusza SW, Myskowski PL, Lieb JA, Saltz L, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25(34):5390–6.

    Article  PubMed  CAS  Google Scholar 

  14. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008;113(4):847–53.

    Article  PubMed  CAS  Google Scholar 

  15. Lacouture ME. The growing importance of skin toxicity in EGFR inhibitor therapy. Oncology (Williston Park, NY). 2009;23(2):194. 196.

    Google Scholar 

  16. Kerob D, Dupuy A, Reygagne P, Levy A, Morel P, Bernard BA, et al. Facial hypertrichosis induced by Cetuximab, an anti-EGFR monoclonal antibody. Arch Dermatol. 2006;142(12):1656–7.

    Article  PubMed  Google Scholar 

  17. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579–91.

    Article  PubMed  CAS  Google Scholar 

  18. Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol. 2005;74(2):121–3.

    Article  PubMed  CAS  Google Scholar 

  19. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003;48(2):201–6.

    Article  PubMed  Google Scholar 

  20. Basso FG, Boer CC, Corrêa MEP, Torrezan M, Cintra ML, de Magalhães MHCG, et al. Skin and oral lesions associated to imatinib mesylate therapy. Support Care Cancer. 2009;17(4):465–8.

    Article  PubMed  Google Scholar 

  21. Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med. 2001;345(8):618–9.

    Article  PubMed  CAS  Google Scholar 

  22. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645–52.

    Article  PubMed  CAS  Google Scholar 

  23. Deininger MWN, O’Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21(8):1637–47.

    Article  PubMed  CAS  Google Scholar 

  24. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol. 2006;5(3):228–31.

    PubMed  Google Scholar 

  25. Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol. 2003;40(2 Suppl 2):21–5.

    Article  PubMed  CAS  Google Scholar 

  26. Hsiao L-T, Chung H-M, Lin J-T, Chiou T-J, Liu J-H, Fan FS, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol. 2002;117(3):620–2.

    Article  PubMed  Google Scholar 

  27. Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother. 2005;39(1):162–4.

    PubMed  Google Scholar 

  28. Vidal D, Puig L, Sureda A, Alomar A. Sti571-induced Stevens-Johnson Syndrome. Br J Haematol. 2002;119(1):274–5.

    Article  PubMed  CAS  Google Scholar 

  29. Pavithran K, Thomas M. Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose. Indian J Dermatol Venereol Leprol. 2005;71(4):288–9.

    Article  PubMed  Google Scholar 

  30. Sanchez-Gonzalez B, Pascual-Ramirez JC, Fernandez-Abellan P, Belinchon-Romero I, Rivas C, Vegara-Aguilera G. Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia. Blood. 2003;101(6):2446.

    Article  PubMed  CAS  Google Scholar 

  31. Mahapatra M, Mishra P, Kumar R. Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose. Ann Hematol. 2007;86(7):537–8.

    Article  PubMed  Google Scholar 

  32. Brouard MC, Prins C, Mach-Pascual S, Saurat JH. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology (Basel). 2001;203(1):57–9.

    Article  CAS  Google Scholar 

  33. Schwarz M, Kreuzer K-A, Baskaynak G, Dörken B, le Coutre P. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol. 2002;69(4):254–6.

    Article  PubMed  Google Scholar 

  34. Le Nouail P, Viseux V, Chaby G, Billet A, Denoeux JP, Lok C. Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy. Ann Dermatol Venereol. 2006;133(8–9 Pt 1):686–8.

    Article  PubMed  Google Scholar 

  35. Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542–51.

    Article  PubMed  Google Scholar 

  36. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540–6.

    Article  PubMed  CAS  Google Scholar 

  37. Woo SM, Huh CH, Park KC, Youn SW. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib. J Dermatol. 2007;34(10):724–6.

    Article  PubMed  Google Scholar 

  38. Brazzelli V, Prestinari F, Roveda E, Barbagallo T, Bellani E, Vassallo C, et al. Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases. J Am Acad Dermatol. 2005;53(5 Suppl 1):S240–3.

    Article  PubMed  Google Scholar 

  39. Konstantopoulos K, Papadogianni A, Dimopoulou M, Kourelis C, Meletis J. Pityriasis rosea associated with imatinib (STI571, Gleevec). Dermatology (Basel). 2002;205(2):172–3.

    Article  CAS  Google Scholar 

  40. Deguchi N, Kawamura T, Shimizu A, Kitamura R, Yanagi M, Shibagaki N, et al. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukemia. Br J Dermatol. 2006;154(6):1216–8.

    PubMed  CAS  Google Scholar 

  41. Kuraishi N, Nagai Y, Hasegawa M, Ishikawa O. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature. Acta Derm Venereol. 2010;90(1):73–6.

    Article  PubMed  CAS  Google Scholar 

  42. Gómez Fernández C, Sendagorta Cudós E, Casado Verrier B, Feito Rodríguez M, Suárez Aguado J, VidaurrázagaDíazdeArcaya C. Oral lichenoid eruption associated with imatinib treatment. Eur J Dermatol. 2010;20(1):127–8.

    PubMed  Google Scholar 

  43. Kawakami T, Kawanabe T, Soma Y. Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia. Acta Derm Venereol. 2009;89(3):325–6.

    Article  PubMed  Google Scholar 

  44. Sendagorta E, Herranz P, Feito M, Ramírez P, Feltes R, Floristán U, et al. Lichenoid drug eruption related to imatinib: report of a new case and review of the literature. Clin Exp Dermatol. 2009;34(7):e315–6.

    Article  PubMed  CAS  Google Scholar 

  45. Dalmau J, Peramiquel L, Puig L, Fernández-Figueras MT, Roé E, Alomar A. Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. Br J Dermatol. 2006;154(6):1213–6.

    Article  PubMed  CAS  Google Scholar 

  46. Prabhash K, Doval DC. Lichenoid eruption due to imatinib. Indian J Dermatol Venereol Leprol. 2005;71(4):287–8.

    Article  PubMed  CAS  Google Scholar 

  47. Ena P, Chiarolini F, Siddi GM, Cossu A. Oral lichenoid eruption secondary to imatinib (Glivec). J Dermatolog Treat. 2004;15(4):253–5.

    Article  PubMed  CAS  Google Scholar 

  48. Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol. 2004;15(2):358–9.

    Article  PubMed  CAS  Google Scholar 

  49. Tsao AS, Kantarjian H, Cortes J, O’Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2003;98(11):2483–7.

    Article  PubMed  Google Scholar 

  50. Etienne G, Cony-Makhoul P, Mahon F-X. Imatinib mesylate and gray hair. N Engl J Med. 2002;347(6):446.

    Article  PubMed  Google Scholar 

  51. Mcpherson T, Sherman V, Turner R. Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol. 2009;23(1):82–3.

    Article  PubMed  CAS  Google Scholar 

  52. Dippel E, Haas N, Grabbe J, Schadendorf D, Hamann K, Czarnetzki BM. Expression of the c-kit receptor in hypomelanosis: a comparative study between piebaldism, naevus depigmentosus and vitiligo. Br J Dermatol. 1995;132(2):182–9.

    Article  PubMed  CAS  Google Scholar 

  53. Cario-André M, Ardilouze L, Pain C, Gauthier Y, Mahon F-X, Taieb A. Imatinib mesilate inhibits melanogenesis in vitro. Br J Dermatol. 2006;155(2):493–4.

    Article  PubMed  Google Scholar 

  54. Hamm M, Touraud JP, Mannone L, Klisnick J, Ponnelle T, Lambert D. Imatinib-induced purpuric vasculitis. Ann Dermatol Venereol. 2003;130(8–9 Pt 1):765–7.

    PubMed  CAS  Google Scholar 

  55. Clark SH, Duvic M, Prieto VG, Prietol VG. Mycosis fungoides-like reaction in a patient treated with Gleevec. J Cutan Pathol. 2003;30(4):279–81.

    Article  PubMed  Google Scholar 

  56. Rousselot P, Larghero J, Raffoux E, Calvo F, Tulliez M, Giraudier S, et al. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. Br J Haematol. 2003;120(6):1091–2.

    Article  PubMed  Google Scholar 

  57. Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010;18(4):509–22.

    Article  PubMed  Google Scholar 

  58. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531–41.

    Article  PubMed  CAS  Google Scholar 

  59. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303–9.

    Article  PubMed  CAS  Google Scholar 

  60. Robert C. Cutaneous side effects of antiangiogenic agents. Bull Cancer. 2007;94 Spec No:S260–4.

    Google Scholar 

  61. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009;60(2):299–305.

    Article  PubMed  Google Scholar 

  62. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293–300.

    Article  PubMed  CAS  Google Scholar 

  63. Blumenschein Jr GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(26):4274–80.

    Article  PubMed  CAS  Google Scholar 

  64. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.

    Article  PubMed  CAS  Google Scholar 

  65. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312–8.

    Article  PubMed  CAS  Google Scholar 

  66. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698–711.

    Article  PubMed  Google Scholar 

  67. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505–12.

    Article  PubMed  CAS  Google Scholar 

  68. Ryan CW, Goldman BH, Lara Jr PN, Mack PC, Beer TM, Tangen CM, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007;25(22):3296–301.

    Article  PubMed  CAS  Google Scholar 

  69. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–38.

    Article  PubMed  CAS  Google Scholar 

  70. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10(8):757–63.

    Article  PubMed  CAS  Google Scholar 

  71. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    Article  PubMed  CAS  Google Scholar 

  72. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15(12):4220–7.

    Article  PubMed  CAS  Google Scholar 

  73. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.

    Article  PubMed  CAS  Google Scholar 

  74. Hutson TE, Davis ID, Machiels J-PH, De Souza PL, Rottey S, Hong B-F, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010;28(3):475–80.

    Article  PubMed  CAS  Google Scholar 

  75. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40(3):367–98; quiz 399–400.

    Article  PubMed  CAS  Google Scholar 

  76. von Moos R, Thuerlimann BJK, Aapro M, Rayson D, Harrold K, Sehouli J, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer. 2008;44(6):781–90.

    Article  CAS  Google Scholar 

  77. Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs. 2007;11(3):238–46.

    Article  PubMed  Google Scholar 

  78. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144(7):886–92.

    Article  PubMed  CAS  Google Scholar 

  79. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77(5):257–71.

    Article  PubMed  CAS  Google Scholar 

  80. Autier J, Mateus C, Wechsler J, Spatz A, Robert C. Cutaneous side effects of sorafenib and sunitinib. Ann Dermatol Venereol. 2008;135(2):148–53; quiz 147, 154.

    Article  PubMed  CAS  Google Scholar 

  81. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008;19(11):1955–61.

    Article  PubMed  CAS  Google Scholar 

  82. Yang C-H, Lin W-C, Chuang C-K, Chang Y-C, Pang S-T, Lin Y-C, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008;158(3):592–6.

    Article  PubMed  CAS  Google Scholar 

  83. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13(9):1001–11.

    Article  PubMed  CAS  Google Scholar 

  84. Robert C, Faivre S, Raymond E, Armand J-P, Escudier B. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med. 2005;143(4):313–4.

    PubMed  Google Scholar 

  85. Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045–51.

    Article  PubMed  CAS  Google Scholar 

  86. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–90.

    Article  PubMed  CAS  Google Scholar 

  87. Kong HH, Turner ML. Array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol. 2009;61(2):360–1.

    Article  PubMed  Google Scholar 

  88. MacGregor JL, Silvers DN, Grossman ME, Sherman WH. Sorafenib-induced erythema multiforme. J Am Acad Dermatol. 2007;56(3):527–8.

    Article  PubMed  Google Scholar 

  89. Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol. 2008;144(6):820–2.

    Article  PubMed  Google Scholar 

  90. Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008;16(6):557–66.

    Article  PubMed  CAS  Google Scholar 

  91. Robert C, Spatz A, Faivre S, Armand J-P, Raymond E. Tyrosine kinase inhibition and grey hair. Lancet. 2003;361(9362):1056.

    Article  PubMed  Google Scholar 

  92. Hartmann JT, Kanz L. Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol. 2008;144(11):1525–6.

    Article  PubMed  Google Scholar 

  93. Billemont B, Barete S, Rixe O. Scrotal cutaneous side effects of sunitinib. N Engl J Med. 2008;359(9):975–6; discussion 976.

    Article  PubMed  CAS  Google Scholar 

  94. Suwattee P, Chow S, Berg BC, Warshaw EM. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Arch Dermatol. 2008;144(1):123–5.

    Article  PubMed  Google Scholar 

  95. Guevremont C, Alasker A, Karakiewicz PI. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr Opin Support Palliat Care. 2009;3(3):170–9.

    Article  PubMed  Google Scholar 

  96. Bennani-Lahlou M, Mateus C, Escudier B, Massard C, Soria J-C, Spatz A, et al. Eruptive nevi associated with sorafenib treatment. Ann Dermatol Venereol. 2008;135(10):672–4.

    Article  PubMed  CAS  Google Scholar 

  97. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell. 2009;15(4):294–303.

    Article  PubMed  CAS  Google Scholar 

  98. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008;132(3):363–74.

    Article  PubMed  CAS  Google Scholar 

  99. Arnault JP, Wechsler J, Escudier B, Spatz A, Tomasic G, Sibaud V, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol. 2009;27(23):e59–61.

    Article  PubMed  Google Scholar 

  100. Kwon EJ, Kish LS, Jaworsky C. The histologic spectrum of epithelial neoplasms induced by sorafenib. J Am Acad Dermatol. 2009;61(3):522–7.

    Article  PubMed  CAS  Google Scholar 

  101. Clausen OPF, Aass HCD, Beigi M, Purdie KJ, Proby CM, Brown VL, et al. Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol. 2006;126(10):2308–15.

    Article  PubMed  CAS  Google Scholar 

  102. Cribier B, Asch P, Grosshans E. Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatology (Basel). 1999;199(3):208–12.

    Article  CAS  Google Scholar 

  103. Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol. 1993;15(4):332–42; discussion 343–52.

    Article  PubMed  CAS  Google Scholar 

  104. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol. 1997;9(2):180–6.

    Article  PubMed  CAS  Google Scholar 

  105. Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am. 2009;23(3):529–45, ix.

    Article  PubMed  Google Scholar 

  106. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209–21.

    Article  PubMed  CAS  Google Scholar 

  107. Mateus C, Robert C. New drugs in oncology and skin toxicity. Rev Med Interne. 2009;30(5):401–10.

    Article  PubMed  CAS  Google Scholar 

  108. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427–30.

    Article  PubMed  CAS  Google Scholar 

  109. Arnault J-P, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, et al. Skin tumors induced by sorafenib; Paradoxical RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53 and TGFBR1. Clin Cancer Res [Internet]. 2012;18(1):263–72. Epub 2011 Nov 17. Available de: http://www.ncbi.nlm.nih.gov/pubmed/22096025. Cité 2011 Dec 18.

  110. Robert C, Arnault J-P, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2011;23(2):177–82.

    Article  PubMed  CAS  Google Scholar 

  111. Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009;27(27):4536–41.

    Article  PubMed  CAS  Google Scholar 

  112. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.

    Article  PubMed  CAS  Google Scholar 

  113. O’Donnell A, Faivre S, Burris 3rd HA, Rea D, Papadimitrakopoulou V, Shand N, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008;26(10):1588–95.

    Article  PubMed  CAS  Google Scholar 

  114. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 2008;26(10):1603–10.

    Article  PubMed  CAS  Google Scholar 

  115. Punt CJA, Boni J, Bruntsch U, Peters M, Thielert C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol. 2003;14(6):931–7.

    Article  PubMed  CAS  Google Scholar 

  116. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22(12):2336–47.

    Article  PubMed  CAS  Google Scholar 

  117. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–19.

    Article  PubMed  CAS  Google Scholar 

  118. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207–15.

    Article  PubMed  CAS  Google Scholar 

  119. Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;365(15):1448–9; author reply 1450.

    Article  PubMed  CAS  Google Scholar 

  120. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.

    Article  PubMed  CAS  Google Scholar 

  121. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–14.

    Article  PubMed  CAS  Google Scholar 

  122. Bjelogrlić SK, Srdić T, Radulović S. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer. J BUON. 2006;11(3):267–76.

    PubMed  Google Scholar 

  123. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31(5):335–40.

    Article  PubMed  CAS  Google Scholar 

  124. Nguyen A, Hoang V, Laquer V, Kelly KM. Angiogenesis in cutaneous disease: part I. J Am Acad Dermatol. 2009;61(6):921–42; quiz 943–4.

    Article  PubMed  CAS  Google Scholar 

  125. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer. 2009;115(11):2438–46.

    Article  PubMed  CAS  Google Scholar 

  126. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22(5):909–18.

    Article  PubMed  CAS  Google Scholar 

  127. Atkins MB, Yasothan U, Kirkpatrick P. Everolimus. Nat Rev Drug Discov. 2009;8(7):535–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Caroline Robert M.D., Ph.D. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Robert, C., Mateus, C., Eggermont, A.M.M. (2013). Dermatologic Side Effects of Systemic Anticancer Therapy. In: Dicato, M. (eds) Side Effects of Medical Cancer Therapy. Springer, London. https://doi.org/10.1007/978-0-85729-787-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-787-7_10

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-786-0

  • Online ISBN: 978-0-85729-787-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics